Merck & Co Expands C Diff Franchise With US Zinplava Approval
Merck & Co is planning a first-quarter 2017 launch of Zinplava, its novel therapy for use in Clostridium difficile infection, following a US FDA approval, strengthening the company’s leading position in an infectious disease with great unmet need.
You may also be interested in...
Pfizer’s Clostridioides difficile vaccine candidate missed a Phase III primary endpoint but the company may seek a path forward based on secondary endpoints even after past failures in the field.
The latest drug development news and highlights from our US FDA Performance Tracker.
Company believes there is a path forward for developing ribaxamase in Phase III, based on discussions with the FDA, but deaths in Phase II meant loss of breakthrough designation.